Welcome to our dedicated page for Ludwig Enter SEC filings (Ticker: LUDG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ludwig Enterprises, Inc. (LUDG) SEC filings page on Stock Titan provides direct access to the company’s official regulatory disclosures, including registration statements, current reports, and other documents filed with the U.S. Securities and Exchange Commission. These filings are the primary source for detailed information on Ludwig Enterprises’ genomics-based diagnostic business, capital structure, risk factors, and corporate governance.
In its S-1/A registration statement, Ludwig Enterprises describes itself as an early-stage, genomics-based diagnostic company focused on mRNA testing for inflammation-related chronic diseases, including cancers. The filing outlines the company’s use of non-invasive buccal cheek swabs, mRNA isolation, and targeted sequencing, as well as its status as an emerging growth company and smaller reporting company. It also discusses a proposed firm commitment public offering, planned reverse stock split parameters, and the intention to apply for listing on a national securities exchange in connection with that offering.
Current reports on Form 8-K, such as the filing announcing the appointment of an Interim Chief Executive Officer, document material events including leadership changes and other significant corporate actions. These filings help investors understand shifts in management responsibilities and the company’s evolving organizational structure as it advances its Revealia™ cancer screening program and related initiatives.
On Stock Titan, Ludwig Enterprises’ filings are updated as new documents are posted to the SEC’s EDGAR system. Users can review registration statements for business descriptions and risk factors, 8-Ks for key events, and other filings that may be added over time. AI-powered summaries highlight the main points of lengthy documents, helping readers quickly identify disclosures related to mRNA diagnostics, AI-driven screening technology, financing plans, and governance matters without having to parse every page manually.
Ludwig Enterprises is registering 3,750,002 Common Units in a firm-commitment public offering. Each unit includes one share of common stock and one tradeable warrant, with an assumed price of $4.00 per unit and a warrant exercise price of $5.00, expiring five years after issuance.
The company expects net proceeds of approximately $13,550,006, or $15,620,002 if the over-allotment is fully exercised, to fund sales and marketing, research and clinical studies, general and administrative expenses, working capital and repayment of $1,092,000 in unsecured and OID debt. A 1-for-100 reverse stock split, subject to FINRA approval, is planned to support uplisting, and the offering will not close without an exchange listing.
Ludwig is an early-stage genomics company developing mRNA cheek-swab tests for inflammation-related diseases such as cancers and heart disease. It has had minimal revenue, recurring net losses, a substantial accumulated deficit and a going-concern warning, and it will need additional capital beyond this offering to complete planned clinical studies and commercialize its products.
Ludwig Enterprises, Inc. entered into a funding deal with Alumni Capital LP involving a $250,000 convertible promissory note and a common stock purchase warrant. The note, issued at an original issue discount, matures on May 4, 2026 and becomes convertible after an event of default at a price equal to 70% of the lowest traded price of the common stock over the 20 business days before conversion notice.
The warrant allows Alumni Capital to buy up to 4,166,667 shares of common stock at $0.06 per share, exercisable from February 5, 2026 for five years. These securities, and the shares underlying them, were issued in a private placement relying on Section 4(a)(2) and/or Regulation D, with no commissions paid.
Ludwig Enterprises (LUDG) reported Q3 2025 results. The company posted net income of $31,252 for the quarter, driven largely by a $630,586 gain from the change in fair value of a derivative liability, while operations remained unprofitable. For the nine months, it recorded a net loss of $1,159,135 on $0 revenue as it continues developing mRNA-based diagnostics.
Liquidity is tight. Cash was $3,317 at September 30, 2025, with a working capital deficit of $3,319,663, notes payable of $1,270,009 and convertible notes payable of $687,593. Total liabilities were $3,572,502 and stockholders’ deficit was $(3,310,908). Management disclosed substantial doubt about the company’s ability to continue as a going concern.
Operating expenses reached $1,481,907 year-to-date, reflecting increased consulting, professional fees, and R&D. Financing provided $637,150 net cash year-to-date. The derivative liability stood at $267,473 at quarter-end. Shares outstanding were 162,569,807 as of November 5, 2025. Management said potential product sales could begin in Q4 2025, assuming approximately $10,000,000 of funding, with no assurance.
Ludwig Enterprises, Inc. (OTC: LUDG) filed Amendment No. 1 to its Form S-1 for a firm commitment public offering of common stock. The transaction is a primary issuance, with proceeds to the company, and is planned to begin as soon as practicable after the registration statement is declared effective. The offering is contingent on approval to list the common stock on a national exchange and on completing a reverse stock split “within a range from one-for-fifty to one-for-two-hundred-fifty.” If listing approval is not obtained, the company will terminate the offering.
The company plans to use proceeds for equipment, marketing, staffing, legal and accounting, company awareness, research and clinical trials, debt repayment, and to exercise an option to buy back certain shares. Prior to the offering, 162,569,807 shares of common stock were outstanding (without giving effect to the reverse split). The company states that, upon the effectiveness of the offering and its amended and restated articles, all outstanding Convertible Preferred Stock will automatically convert into common stock, and a portion of its convertible notes will convert into common stock.
Ludwig is an early-stage genomics diagnostics company focused on mRNA-based tests and qualifies as both an emerging growth company and a smaller reporting company. Recent financials show minimal revenue and net losses, and the auditors noted substantial doubt about the company’s ability to continue as a going concern.
Ludwig Enterprises, Inc. appointed Jose Antonio Reyes as Interim Chief Executive Officer. The Board of Directors approved his appointment effective October 1, 2025. Reyes currently serves as Senior Head of Global Business Development and will continue in that role.
Reyes brings extensive familiarity with the company, having previously served as Chief Executive Officer from August 2024 to April 2025 and as Chief Operating Officer from February 2023. He also has over 30 years of leadership experience in executive education, business development, and strategy roles at companies including BlockScience, IGM Global, Excelorators, and Trademark Tours.
As of this filing, the company has not entered into any compensatory agreements related to his Interim CEO role. The Compensation Committee expects to review and determine appropriate compensation, and any resulting arrangements will be disclosed in an amended report. The company states there are no arrangements, family relationships, or related-party transactions connected to his appointment.